# GLP-1 vs GIP: The Two Gut Hormones Behind Modern Weight-Loss Drugs

Source: https://www.dietglp.com/blog/glp1-vs-gip-explained/
Published: 2026-01-26
Keywords: glp-1 vs gip, incretin hormones, gip receptor, tirzepatide mechanism

**TL;DR:** GLP-1 and GIP are both released by your gut after eating. GLP-1 strongly suppresses appetite and slows the stomach; GIP enhances insulin response. Tirzepatide activates both, which is why it produces more weight loss than semaglutide. Triple agonists (GLP-1 + GIP + glucagon) are next.

When you hear "GLP-1 drug" you might think the only mechanism is GLP-1. The reality is more interesting. Your gut releases two main "incretin" hormones after a meal — **GLP-1** and **GIP** — and the next generation of weight-loss drugs activates both, then a third receptor on top.

## What each hormone does

**GLP-1 (glucagon-like peptide-1)**
- Released by L cells in the lower small intestine
- Strongly suppresses appetite (brain receptors)
- Slows gastric emptying (this is most of the "fullness")
- Stimulates insulin release in response to glucose
- Suppresses glucagon (reduces liver glucose output)

**GIP (glucose-dependent insulinotropic polypeptide)**
- Released by K cells in the upper small intestine
- Enhances insulin response after a meal
- Has a smaller direct appetite effect
- Affects fat storage in adipose tissue
- Less well-understood role in obesity

## Why activating both matters

When researchers built tirzepatide (a single molecule that hits both receptors), the effect was larger than the sum of the parts. SURMOUNT-1 showed average 21% weight loss at 15 mg vs ~15% for semaglutide at 2.4 mg.

Theories on why:

- **Complementary pathways.** GLP-1 reduces intake; GIP changes how the body partitions stored vs. burned fat.
- **Receptor crosstalk.** Activating both may amplify hypothalamic appetite suppression beyond what either does alone.
- **Better tolerability per unit effect.** Some sub-analyses suggest tirzepatide patients tolerate larger weight loss with fewer side effects than would be expected on equivalent semaglutide doses.

## What's next: triple agonists

Eli Lilly's **retatrutide** activates GLP-1, GIP, **and** the glucagon receptor — the triple-agonist concept. Glucagon, despite its name, has a fat-burning effect when its receptor is activated alongside the other two. Phase 2 results showed average ~24% weight loss at 48 weeks, with some patients losing more than 30%.

Other triple agonists are in development across multiple companies. Phase 3 results will land in the next few years. For the phase 3 TRIUMPH results, side effects and FDA timeline, see our [retatrutide guide](/blog/retatrutide-guide/).

## Other receptor systems on the horizon

- **Amylin agonists** (cagrilintide). Amylin is a separate appetite hormone. Combinations with semaglutide (CagriSema) are in late-stage trials.
- **GLP-1 + glucagon dual agonists** (mazdutide, survodutide).
- **Oral GLP-1s** (oral semaglutide, Pfizer's danuglipron) — less effective than injections so far, but easier to take.

## Practical implication for current patients

This matters less than the press releases suggest. Whether you're on semaglutide, tirzepatide, or eventually retatrutide:

- Stronger appetite suppression = bigger calorie deficit = more pressure on lean mass
- Same protein floor needed
- Same resistance training needed
- Same maintenance plan needed

Better drugs make the muscle-loss risk worse, not better, unless you protect against it deliberately.

## Bottom line

GLP-1 and GIP are two gut hormones with overlapping but distinct effects. Tirzepatide activates both and produces more weight loss than GLP-1-only drugs. Triple-agonist drugs (adding glucagon) are coming and will produce even more weight loss. The fundamentals — protein, lifting, sleep, maintenance — apply to every generation of these drugs.